biopharma-reporter2h
Alentis raises $181 million to advance ADCs to the clinic
The Series D financing will support the clinical development of two ADCs.
biopharma-reporter1d
AbbVie’s schizophrenia candidate fails in two phase 2 trials
Emraclidine was expected to be a competitor to Bristol Myers Squibb’s recently approved Cobenfy, but trial results put its ...
biopharma-reporter2d
FDA removes clinical hold on Novavax’s COVID-19-influenza combo vaccine
The FDA had put a clinical hold on Novavax’s COVID-19-influenza combo vaccine after an adverse event in a patient.
biopharma-reporter6d
Sarepta discontinues development of Duchenne ASO treatment vesleteplirsen
The US biopharma will discontinue development of the Exondys 51 (eteplirsen) follow up treatment to focus on other treatment ...
biopharma-reporter7d
Aditum Bio and Leads Biolabs join forces in new company to fight autoimmune diseases
The two companies have formed Oblenio Bio to develop a tri-specific T-cell engager The U.S. company Aditum Bio and Chinese company Leads Biolabs today announced that they have founded Oblenio Bio, a ...